Personalized Medicine






Ananta (minimally-invasive and conservative surgery) will make it possible to avoid useless sacrifices of healthy tissue with a new imaging device designed to replace generic surgical procedures with targeted ablation and repair procedures adjusted to each patient. 


Basecamp Vascular

BaseCamp Vascular develops a robotically-controlled active guide catheter for endovascular navigation. Bendable on demand, this device allows operators to circumvent complex twists and turns of the arteries during minimally-invasive surgical procedures.


myBrain Technologies

The Covem project aims to develop a brand new medical diagnostic device based on electroencephalography technology. The new tool will introduce an unprecedented indicator that provides reliable, personalized information on respiratory distress that will optimize the treatment of multiple respiratory pathologies. The innovation, developed by the research laboratories of Pitié Salpétrière Hospital (Paris), is a world first in the field of pneumology and has significant commercial potential.



DIAGEN, developed by Traaser, is a genome analysis application designed for physicians. A combination of big data and genetics, it helps in reaching a diagnosis and defining the best course of treatment for patients.


InSimo SAS

The DISPLAY project led by InSimo and supported by the IHU Strasbourg (Institute of Image-Guided Surgery) centers on planning software for gastric surgery. It is based on personalized biomechanical simulation to assist surgeons and reduce risks for patients.

EndoPrint Endodiag To improve the diagnosis of endometriosis, Endodiag develops EndoPrint®, a new minimally invasive test (involving taking a sample of peritoneal fluid) that permits diagnosis and relapse risk determination, so as to guide the definition of the right course of treatment for each patient.

ID2STOP Orphan


APTEEUS offers services for testing any drug from the world’s pharmacopeia on patients’ primary cells (using a biopsy) and, using genetic data, to identify a treatment that is immediately available. 20 million patients in Europe could benefit from this technology.



Development of the first test for identification and proximal measurements of cytotoxic T-cells and tumor cells in lung cancer in order to better identify which patients will be receptive to immunotherapy.

ORTHOSIM TEXISENSE Ortho-Sim is a tool for creating digital clones using patients’ medical imaging results. The clones can then undergo “virtual orthopedic surgery” by simulation, to predict the outcomes of actual surgery.
PEM4IBD Alma Bio Therapeutics SAS Alma is a start-up founded in 2013 at the LyonBiopole. Based on the findings of Dr. Irun Cohen of the Weizmann Institute, Alma “re-trains” the immune system to combat auto-immune diseases.



The purpose of the “PoieSI” project is to allow the Poietis company to develop and manufacture individualized human tissue using its 4D bio-printing technique, for applications in personalized medicine and regenerative medicine.


AP Advance

AP Advance develops a patch for patients suffering from Type 1 diabetes. Light, compact, and easy to place on the abdomen, this miniature artificial pancreas automatically measures the blood sugar level and releases the necessary quantity of insulin.

Silibioprint MEDIMPRINT Medimprint utilizes nanoporous silicon and invents a new concept in tissue imprinting using non-lesional systems able to reach affected regions unexplored yet by research on neurodegenerative diseases.


LLTech Management

The innovation developed by LLTech is a novel type of imaging system for use in skin cancer surgeries. It allows almost real-time biopsy requiring no tissue preparation to reduce cancer relapse rate while minimizing surgical time and costs.



Urotest is an extremely precise test used to monitor bladder cancer. A urine analysis by multiplex quantitative PCR allows very early and non-invasive detection of relapse with considerably enhanced patient comfort.



The solution developed by the very young and highly promising start-up, OncoFactory, provides quick and accurate replicas of each patient’s tumor to test new therapeutic molecules and define personalized treatment.


Connaissez-vous La page Facebook de la DGE ?

Pour suivre toute l'actualité, cliquez sur le bouton « J'aime »